Table 2.
Study 1 exclusion parameters
| Exclusion criteria | Count (out of 319) | Percentage (out of 319) | Notes | Could exclude PBT |
|---|---|---|---|---|
| Not reported | 67 | 21 | Issue of poor reporting and heterogeneity of sample | X |
| Cognitive impairment | 47 | 15 | Often not defined | X |
| Metastatic disease | 52 | 16 | Any metastases | |
| Brain metastases | 5 | 2 | Explicit exclusion of brain metastases | |
| CNS disease/primary brain tumor | 4 | 1 | Explicit exclusion of PBTs | X |
| Off treatment | 81 | 25 | Not currently being treated | X |
| Curative treatment | 13 | 4 | Intent of treatment is to cure | X |
| No recurrent or terminal disease | 63 | 20 | Often poorly defined | X |
| Other | 46 | 14 | For example, ongoing or synchronous disease | X |
| Not explicitly stated | 74 | 23 | Inclusion criteria specified, but nothing specific to the categories above | X |
Categories are not exclusive of one another. Studies could be coded for several exclusion criteria. The number 319 includes the total number of studies that were included in the review